A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

D. Michael Ackermann net worth and biography

D. Ackermann Biography and Net Worth

Director of Tarsus Pharmaceuticals

Michael is a co-founder and Chairman of the Board of Tarsus. He is also co-founder, former CEO, and serves on the board of Presidio Medical. Previously, he served as Chairman of Oyster Point Pharma, Inc. (NASDAQ: OYST). Prior to this, he was Vice President, Neurostimulation for Allergan (an AbbVie company), after serving as CEO of Oculeve, Inc., which was acquired by Allergan.

Michael received a BE degree in biomedical engineering from Vanderbilt University and MS and PhD degrees in biomedical engineering from Case Western Reserve University. He is a graduate of Stanford University’s Biodesign Fellowship and Vision Research Fellowship. He has numerous patents and peer-reviewed publications.

What is D. Michael Ackermann's net worth?: The estimated net worth of D. Michael Ackermann is at least $3.37 million as of May 5th, 2022. Dr. Ackermann owns 100,000 shares of Tarsus Pharmaceuticals stock worth more than $3,371,000 as of April 23rd. This net worth approximation does not reflect any other investments that Dr. Ackermann may own. Learn More about D. Michael Ackermann's net worth.
How do I contact D. Michael Ackermann?: The corporate mailing address for Dr. Ackermann and other Tarsus Pharmaceuticals executives is , , . Tarsus Pharmaceuticals can also be reached via phone at 949-409-9820 and via email at [email protected]. Learn More on D. Michael Ackermann's contact information.
Has D. Michael Ackermann been buying or selling shares of Tarsus Pharmaceuticals?: D. Michael Ackermann has not been actively trading shares of Tarsus Pharmaceuticals during the past quarter. Most recently, on Thursday, May 5th, Michael Ackermann bought 100,000 shares of Tarsus Pharmaceuticals stock. The stock was acquired at an average cost of $13.50 per share, with a total value of $1,350,000.00. Following the completion of the transaction, the director now directly owns 100,000 shares of the company's stock, valued at $1,350,000. Learn More on D. Michael Ackermann's trading history.
Who are Tarsus Pharmaceuticals' active insiders?: Tarsus Pharmaceuticals' insider roster includes D. Ackermann (Director), Bobak Azamian (CEO), and Aziz Mottiwala (Insider). Learn More on Tarsus Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Tarsus Pharmaceuticals?: During the last year, Tarsus Pharmaceuticals insiders bought shares 2 times. They purchased a total of 10,506 shares worth more than $178,660.80. During the last year, insiders at the sold shares 25 times. They sold a total of 281,825 shares worth more than $5,584,852.48. The most recent insider tranaction occured on March, 18th when insider Aziz Mottiwala sold 4,766 shares worth more than $145,839.60. Insiders at Tarsus Pharmaceuticals own 11.5% of the company. Learn More about insider trades at Tarsus Pharmaceuticals.
Information on this page was last updated on 3/18/2024.

D. Michael Ackermann Insider Trading History at Tarsus Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/5/2022	Buy	100,000	$13.50	$1,350,000.00	100,000
12/1/2021	Sell	5,833	$24.68	$143,958.44
11/1/2021	Sell	5,833	$27.82	$162,274.06
10/12/2021	Sell	5,633	$26.27	$147,978.91
10/8/2021	Sell	200	$25.03	$5,006.00
9/1/2021	Sell	5,833	$25.24	$147,224.92	1,221,515
8/11/2021	Sell	621	$25.15	$15,618.15	1,227,348
8/9/2021	Sell	700	$25.00	$17,500.00
8/6/2021	Sell	3,129	$25.00	$78,225.00

D. Michael Ackermann Buying and Selling Activity at Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Company Overview

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Today's Range

Now: $33.71

$32.14

$34.11

50 Day Range

MA: $33.86

$29.43

$39.22

2 Week Range

Now: $33.71

$12.57

$40.40

Volume

230,724 shs

Average Volume

731,767 shs

Market Capitalization

$1.15 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05

SHOCKING Crypto Leak…

From Crypto 101 Media | Ad